Cochlear (COH) Aktievy
Cochlear Limited tillhandahåller implanterbara hörsellösningar för barn och vuxna över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 2/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 3/6 |
COH Community Fair Values
Create NarrativeSee what 72 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$70
FV
73.7% övervärderad intrinsisk rabatt0.14%
Revenue growth p.a.
195
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
Cochlear Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | AU$121.62 |
| 52 veckors högsta | AU$319.56 |
| 52 veckors lägsta | AU$88.74 |
| Beta | 0.26 |
| 1 månads förändring | 18.20% |
| 3 månaders förändring | -29.33% |
| 1 års förändring | -59.92% |
| 3 års förändring | -47.20% |
| 5 års förändring | -49.17% |
| Förändring sedan börsintroduktionen | 4,022.71% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Analysartikel • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...
Uppdatering av berättelse • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Uppdatering av berättelse • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Recent updates
Uppdatering av berättelse • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Analysartikel • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...Uppdatering av berättelse • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Uppdatering av berättelse • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Uppdatering av berättelse • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
Ny berättelse • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Uppdatering av berättelse • Apr 21
COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments
The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.Uppdatering av berättelse • Apr 04
COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside
Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.Uppdatering av berättelse • Mar 21
COH: VA Access Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.Uppdatering av berättelse • Mar 06
COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential
Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.Ny berättelse • Mar 01
Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability
Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Feb 20
COH: Reset Expectations And Product Adoption Will Support Future Upside Potential
Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.Analysartikel • Feb 16
Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...Analysartikel • Feb 15
Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%
Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Ny berättelse • Feb 13
Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion
Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Analysartikel • Feb 06
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Uppdatering av berättelse • Feb 05
COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential
Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.Analysartikel • Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysartikel • Nov 18
Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...Analysartikel • Oct 14
Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Sep 28
We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Uppdatering av berättelse • Sep 19
Aging Population Will Spur Cochlear Implant Adoption Worldwide
Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.Analysartikel • Aug 26
Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...Uppdatering av berättelse • Aug 19
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.Analysartikel • Jul 16
Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Ny berättelse • Feb 23
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.Aktieägarnas avkastning
| COH | AU Medical Equipment | AU Marknad | |
|---|---|---|---|
| 7D | -2.7% | -2.9% | -0.4% |
| 1Y | -59.9% | -44.0% | 2.0% |
Avkastning vs industri: COH presterade sämre än Australian Medical Equipment branschen som gav -44 % under det senaste året.
Avkastning vs Marknaden: COH presterade sämre än Australian marknaden som gav 2 % under det senaste året.
Prisvolatilitet
| COH volatility | |
|---|---|
| COH Average Weekly Movement | 12.6% |
| Medical Equipment Industry Average Movement | 9.7% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.9% |
Stabil aktiekurs: COH har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Australian.
Volatilitet över tid: COH s veckovolatilitet har ökat från 7% till 13% under det senaste året, men är fortfarande lägre än 75 % av Australian aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1981 | 5,500 | Dig Howitt | www.cochlear.com |
Cochlear Limited tillhandahåller implanterbara hörsellösningar för barn och vuxna över hela världen. Företaget erbjuder cochleaimplantatsystem, uppgraderingar av ljudprocessorer, benledningssystem och andra produkter. Företaget tillhandahåller också cochlea nucleus-system, inklusive Nucleus ljudprocessorer, smart bimodal hörsellösning och Nucleus implantat; cochlea Baha-system, inklusive Baha 6 max ljudprocessor och Baha implantat; och tillbehör, såsom trådlösa enheter och Nucleus vattensäkra tillbehör.
Cochlear Limited Sammanfattning av grunderna
| COH grundläggande statistik | |
|---|---|
| Börsvärde | AU$7.95b |
| Vinst(TTM) | AU$345.30m |
| Intäkter(TTM) | AU$2.34b |
23.0x
P/E-förhållande3.4x
P/S-förhållandeÄr COH övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| COH resultaträkning (TTM) | |
|---|---|
| Intäkter | AU$2.34b |
| Kostnad för intäkter | AU$636.90m |
| Bruttovinst | AU$1.70b |
| Övriga kostnader | AU$1.36b |
| Intäkter | AU$345.30m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Aug 18, 2026
| Vinst per aktie (EPS) | 5.28 |
| Bruttomarginal | 72.76% |
| Nettovinstmarginal | 14.77% |
| Skuld/egenkapitalförhållande | 0.7% |
Hur har COH utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
3.5%
Aktuell utdelningsavkastning81%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/11 19:55 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cochlear Limited bevakas av 26 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Stuart Roberts | Bell Potter |
| Elisabeth Decou Clive | Bernstein |